Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

The neoadjuvant/adjuvant pembrolizumab and chemotherapy combination was approved by the FDA in October 2023 for use in this patient population.

Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC

Zongertinib demonstrated durable efficacy in patients with pretreated advanced HER2-mutant non–small cell lung cancer.

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC 

Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.

Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab

The phase 3 TROPiCS-04 study missed its primary end point of improved OS with sacituzumab govitecan vs chemotherapy in patients with urothelial cancer.

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

Articles

The FDA awards accelerated approval to encorafenib regimen in BRAF V600E+ CRC, ensartinib wins approval in ALK+ non–small cell lung cancer, and more.

The OncFive: Top Oncology Articles for the Week of 12/15


Gina Mauro is your lead editorial contact for 

. She joined the company in 2015 and has held various positions on 

; she is also the on-air correspondent for 

. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com 

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

Adding dostarlimab to chemotherapy and niraparib maintenance improved progression-free survival in first-line advanced ovarian cancer.

Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

The addition of pegcrisantaspase to venetoclax may overcome resistance to prior BCL-2 inhibitor–based regimens for patients with relapsed/refractory AML. 

Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

The Role of Tyrosine Kinase Inhibitors in Unresectable Hepatocellular Carcinoma

Clinical

Video Series

Comorbidity Considerations for HCC Treatment

Videos

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, discuss the role of tyrosine kinase inhibitors in unresectable hepatocellular carcinoma, second-line treatment options, and recent clinical trials.

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, discuss driving forces for the development of hepatocellular carcinoma, including different types of viral hepatitis and non-alcoholic steatohepatitis.

Examining the Role of Liver Function in HCC

The key opinion leaders discuss staging systems they use in clinical practice and their effectiveness in creating treatment algorithms, particularly with respect to Child-Pugh scores.

HCC Staging: Improving Treatment Strategies

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, review locoregional therapies for hepatocellular carcinoma, including transarterial chemoembolization (TACE) and radioembolization.

Locoregional Therapies for Intermediate-Stage HCC

Medical experts discuss the LAUNCH study, EMERALD-1, and LEAP-012 trials, providing updates on the progress and findings that influence the treatment paradigm for hepatocellular carcinoma.

HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials

The panelists examine the effectiveness of transarterial chemoembolization (TACE) in treating hepatocellular carcinoma in patients with intermediate-stage disease and discuss the future prospects for these patients. 

Emerging Therapies in Intermediate-Stage HCC 

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, provide an overview of the IMbrave150 study, the LEAP-002 trial, and the HIMALAYA trial, discussing how these trials have changed the treatment landscape for hepatocellular carcinoma. 

Updates from IMbrave150, LEAP-002, and HIMALAYA Trials 

The panelists discuss factors that may preclude patients from receiving certain therapies, such as cardiovascular comorbidities, which may pose an immediate threat to the patient's life.

Medical experts discuss the selection of second-line treatments for patients who experience disease progression while on first-line therapy, highlighting the potential for deterioration in performance status and liver function.

The Evolving Landscape of Second-Line Therapies in HCC Management

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, discuss a novel therapy that, although not practice-changing, provides an additional treatment option for patients with hepatocellular carcinoma. 

Additional Second-Line Treatments for HCC

Medical experts discuss how the time to progression, progression patterns, and real-world data influence the provider's choice of treatment for patients with hepatocellular carcinoma. 

Real-World Evidence on Second-Line Therapy Selection and Outcomes 

In their concluding remarks, Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, express their hopes for future advancements in hepatocellular carcinoma (HCC) treatment, including cellular-based therapies, antibody-drug conjugates, and an increased focus on neoadjuvant studies.

Comorbidity Considerations for HCC Treatment

EP: 1.Examining the Role of Liver Function in HCC

EP: 2.HCC Staging: Improving Treatment Strategies

EP: 3.Locoregional Therapies for Intermediate-Stage HCC

EP: 4.HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials

EP: 5.Emerging Therapies in Intermediate-Stage HCC

EP: 6.Updates from IMbrave150, LEAP-002, and HIMALAYA Trials

EP: 7.Comorbidity Considerations for HCC Treatment

EP: 8.The Evolving Landscape of Second-Line Therapies in HCC Management

EP: 9.Additional Second-Line Treatments for HCC

EP: 10.Real-World Evidence on Second-Line Therapy Selection and Outcomes

EP: 11.Pioneering Breakthroughs in HCC Treatment

Latest Conference Coverage